Automate Your Wheel Strategy on MRUS
With Tiblio's Option Bot, you can configure your own wheel strategy including MRUS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRUS
- Rev/Share 0.7909
- Book/Share 11.8393
- PB 7.9768
- Debt/Equity 0.0131
- CurrentRatio 8.3893
- ROIC -0.3982
- MktCap 7143083484.0
- FreeCF/Share -4.407
- PFCF -22.7979
- PE -17.4165
- Debt/Assets 0.0112
- DivYield 0
- ROE -0.5529
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRUS | Barclays | -- | Overweight | -- | $112 | Sept. 17, 2025 |
| Initiation | MRUS | Alliance Global Partners | -- | Buy | -- | $90 | Aug. 25, 2025 |
| Initiation | MRUS | Piper Sandler | -- | Overweight | -- | $84 | Feb. 13, 2025 |
| Initiation | MRUS | Wells Fargo | -- | Overweight | -- | $91 | Feb. 7, 2025 |
News
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: G MAB ) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“ Purchaser ”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of Merus N.V.
Read More
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: October 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m.
Read More
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Read More
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Positive
MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rates could drive long-term value if validated in future studies.
Read More
Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
- 63% response rate observed among 43 evaluable patients - 79% overall survival rate at 12-months; 9 months median progression-free survival - Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.
Read More
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.
Read More
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
Read More
Merus to Present at Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Read More
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Read More
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Read More
About Merus N.V. (MRUS)
- IPO Date 2016-05-19
- Website https://www.merus.nl
- Industry Biotechnology
- CEO Sven Ante Lundberg
- Employees 260